Biopharmaceuticals / Drug Delivery Technology Licensing
Strategic Profile
Halozyme's acquisitions of Elektrofi and Surf Bio extend its IP runway beyond the 2027 ENHANZE patent expiration, supporting long-term revenue sustainability. The three most successful ENHANZE-enabled products include Johnson & Johnson's Darzalex Faspro for multiple myeloma, argenx's VYVGART Hytrulo for myasthenia gravis, and Roche's Phesgo for HER2-positive breast cancer. The Surf Bio acquisition adds a hyperconcentration technology achieving approximately 500 mg/mL concentrations—3-4x higher than typical formulations.
Cyborg Score Rationale
Halozyme is poised to bring in more than $1 billion in royalty revenue alone in 2026, one year earlier than previously projected, with year-over-year royalty growth of 30-35% representing roughly 100% revenue growth over two years ago. At 16x earnings, HALO trades below peers at 19.9x and the US Biotech industry at 22.8x, suggesting a valuation discount. Patent cliff risks remain despite recent acquisitions.
Top Insights
Royalty revenue will exceed $1 billion in 2026—one full year ahead of the timeline CEO Helen Torley set in 2018.
Halozyme expects to make one-to-three new deals for the use of ENHANZE in emerging drug platforms in 2026 and each subsequent year, and potential launch of up to six ENHANZE-enabled therapeutics in 2026.
The company acquired Surf Bio, Inc., a biopharmaceutical company with an innovative, biologic hyperconcentration technology, in December 2025.
2026 revenue outlook raised to US$1.71b to US$1.81b, with 36% to 38% year on year growth in 2025.
Named Competitors
Heron Therapeutics — Drug delivery and oncolytics focused biotech
Alteogen — Biopharmaceutical drug delivery platform